$ILMN

ILLUMINA, INC.

Illumina provides sequencing- and array-based solutions to customers in research, clinical and applied markets. Its products support work in life sciences, oncology, reproductive health, agriculture and other emerging segments. Customers include genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical and biotechnology companies, commercial molecular diagnostic laboratories, and consumer genomics companies. Illumina makes money from sales of instruments and consumables used in genetic analysis, as well as genotyping and sequencing services, instrument service contracts, and development and licensing agreements. It recognizes product revenue generally upon delivery, and service revenue as services are performed. Illumina is headquartered in San Diego, California.

2
1
1
—
$127.7M
Meister Keith A.
3%
See all $ILMN insider activity →

Illumina announces layoffs at San Diego headquarters

Illumina plans to lay off 51 employees at its San Diego headquarters, spanning various roles. The company cited alignment of resources with priorities and customer needs. Illumina faces challenges from federal funding cuts, tariffs, and China's trade restrictions, which impacted its 2022 revenue. Despite a 4.16% sales increase and 47% profit growth in Q3, shares fell 18% and closed Monday at $198, down 3.5%.

Jefferies reiterates Illumina stock Hold rating on innovation potential

Jefferies maintained a Hold rating on Illumina (ILMN) with a $235 price target, citing innovation in SomaSeq and TruPath. The stock is up 80% year-over-year. Q3 2026 earnings beat estimates, with revenue of $1.17B and EPS of $1.44. Evercore ISI raised its target to $200 but kept an Underperform rating. ILMN's gross margin is 68% on $4.5B revenue, though some analysts cut earnings estimates.

ILMN sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 4 news stories mentioning ILMN (ILLUMINA, INC.). Coverage has skewed bullish: 2 bullish, 1 neutral, and 1 bearish.

Recent ILMN coverage spans financial news, insider activity and technology.

In the last 30 days, ILMN insiders filed 35 SEC Form 4 transactions — no purchases and 35 sales ($127.7M). The most active reporter was Meister Keith A. with 34 filings. 3% of those filings were made under pre-arranged Rule 10b5-1 plans.

What's driving ILMN

AlphAI scores every news story that mentions ILMN with an AI model for sentiment and relevance, and aggregates insider trades from ILLUMINA, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $ILMN

Score

Illumina announces layoffs at San Diego headquarters

Illumina plans to lay off 51 employees at its San Diego headquarters, spanning various roles. The company cited alignment of resources with priorities and customer needs. Illumina faces challenges from federal funding cuts, tariffs, and China's trade restrictions, which impacted its 2022 revenue. Despite a 4.16% sales increase and 47% profit growth in Q3, shares fell 18% and closed Monday at $198, down 3.5%.

Jefferies reiterates Illumina stock Hold rating on innovation potential

Jefferies maintained a Hold rating on Illumina (ILMN) with a $235 price target, citing innovation in SomaSeq and TruPath. The stock is up 80% year-over-year. Q3 2026 earnings beat estimates, with revenue of $1.17B and EPS of $1.44. Evercore ISI raised its target to $200 but kept an Underperform rating. ILMN's gross margin is 68% on $4.5B revenue, though some analysts cut earnings estimates.

Illumina selected to help bring precision medicine into everyday healthcare in Singapore

Illumina (ILMN) was chosen to provide whole-genome sequencing for Singapore's SG-INSIGHT study, part of Phase III of the National Precision Medicine program. The study aims to include 450,000 individuals and use genomic data to inform healthcare decisions. Illumina will perform sequencing in Singapore and comply with local regulations. The project builds on Illumina's existing multi-year engagement with Singapore's precision medicine initiatives.

Illumina advances MRD research portfolio with ultrasensitive duplex sequencing technology

Illumina (ILMN) launched an early access program for an ultrasensitive sequencing workflow to detect circulating tumor DNA (ctDNA) in plasma samples. The technology, optimized for high accuracy, can detect ctDNA at 2.5 parts per million with low sample input. NYU Langone Health is an early adopter, and kits are expected to ship in Q1 2027. The workflow complements Illumina's existing MRD research portfolio.

$ILMNMedContract· supplier

Illumina selected to help bring precision medicine into everyday healthcare in Singapore

Illumina (ILMN) was selected for the SG-INSIGHT study, part of Singapore's National Precision Medicine program, to provide whole-genome sequencing for 450,000 residents. The study aims to integrate genomic data with healthcare to tailor treatments. Illumina will operate through its local facility, complying with Singapore's regulations. This follows their support in the previous phase of the program.

Related tickers